AOR

The Archives of Ophthalmological Research aims to publish issues related to publish articles of the highest scientific and clinical value at an international level, and accepts articles on these topics. The target audience of the journal included specialists and physicians working in ophthalmology, and other health professionals interested in these fields.

EndNote Style
Index
Case Report
Acute angle-closure glaucoma following repeated periocular botulinum toxin injection for blepharospasm: a case report
Acute angle closure (AAC) is an ophthalmic emergency characterized by sudden elevation of intraocular pressure due to obstruction of aqueous humor outflow. Several systemic and topical medications, including Botulinum toxin, have been implicated in precipitating AAC in susceptible individuals. Botulinum toxin may induce mydriasis through inhibition of acetylcholine release at parasympathetic nerve terminals. We report the case of a 52-year-old woman who developed Botulinum toxin-associated AAC following repeated periocular Botulinum toxin injections for blepharospasm. The patient presented with ocular pain, redness, and blurred vision in the right eye three days after injection. Ophthalmic examination revealed elevated intraocular pressure, corneal edema, shallow anterior chambers, and closed iridocorneal angles on gonioscopy. Additional examination demonstrated hyperopia in the fellow eye, bilateral occludable angles, iris bombe configuration, and relative mid-dilation of the affected pupil, suggesting a pupillary block mechanism. After initial medical treatment, bilateral neodymium (Nd) laser peripheral iridotomy was successfully performed, resulting in normalization of intraocular pressure without recurrence during approximately 12 months of follow-up. Although rare, Botulinum toxin-associated AAC should be considered in patients with occludable angles and other anatomical risk factors. Careful anterior chamber angle assessment before periocular Botulinum toxin administration may help identify patients at risk and prevent vision-threatening complications.


1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267. doi:10.1136/bjo.2005.081224
2. Lai JSM, Gangwani RA. Medication-induced acute angle closure attack. Hong Kong Med J. 2012;18(2):139-145.
3. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87(10):1044-1049. doi:10.1016/S0161-6420(80)35127-0
4. Corridan P, Nightingale S, Mashoudi N, Williams AC. Acute angle-closure glaucoma following Botulinum toxin injection for blepharospasm. Br J Ophthalmol. 1990;74(5):309-310. doi:10.1136/bjo.74.5.309
5. Zheng L, Azar DT. Angle-closure glaucoma following periorbital Botulinum toxin injection. Clin Exp Ophthalmol. 2014;42(7):690-693. doi:10.1111/ceo.12328
6. Levy Y, Kremer I, Shavit S, Korczyn AD. The pupillary effects of retrobulbar injection of Botulinum toxin A in albino rats. Invest Ophthalmol Vis Sci. 1991;32(1):122-125.
7. Lim EC, Seet RC. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion. Acta Neurol Scand. 2008;117(2):73-84. doi:10.1111/j.1600-0404.2007.00966.x
8. Yang MC, Lin KY. Drug-induced acute angle-closure glaucoma: a review. J Curr Glaucoma Pract. 2019;13(3):104-109. doi:10.5005/jp-journals-10028-1266
9. Jain NS, Ruan CW, Dhanji SR, Symes RJ. Psychotropic drug-induced glaucoma: a practical guide to diagnosis and management. CNS Drugs. 2021;35(3):283-297. doi:10.1007/s40263-021-00807-2
10. O’Ryan Araneda FE, Estrin MA. Drug-induced acute-stage narrow-angle glaucoma: a review of the literature. Interam J Health Sci. 2024;5(2):1-12. doi:10.59471/ijhsc2025269
Volume 3, Issue 2, 2026
Page : 31-33
_Footer